Emily Bertram

80 days ago

Skinbiotherapeutics: Manprick gone and other boardroom changes, more shares bought

Folks like the Lemming thought that Skinbiotherapeutics (SBTX) FD Manprick Randhawa was the bees knees and were jolly cross with me for rebranding him for his patent incompetence. In my view he was useless, unable to communicate with serious investors or to stop Stuart Ashman abusing the word accretive and, at least, partially responsible for the cack handed and dilutive financing of two acquisitions. He was unable to control costs. Well, today, he has gone to pursue other business interests. Great news.. It has prompted me to buy more shares, increasing my holding by 25%.